Genomic Vision

Genomic Vision Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Genomic Vision (GV.PA) as of Nov 3, 2026 is -0.37. In the previous year, Net Debt to Free Cash Flow Ratio was 0.28 — a change of -232.53% (lower).

Net Debt/FCF

-0.37

YoY

-232.53%

Last updated:

Net Debt to Free Cash Flow Ratio of Genomic Vision is 2022 -0.37 . Net Debt to Free Cash Flow Ratio of Genomic Vision was 2021 0.28 . It decreases by -232.53% lower compared to the previous year.

The Genomic Vision Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2015
2.20 EUR
Jan 1, 2016
0.79 EUR
Jan 1, 2017
0.13 EUR
Jan 1, 2018
0.46 EUR
Jan 1, 2019
0.19 EUR
Jan 1, 2020
0.22 EUR
Jan 1, 2021
0.28 EUR
Jan 1, 2022
-0.37 EUR
The Genomic Vision Net Debt/FCF history
YEARNet Debt/FCFYoY
-0.37-232.53%
0.28+24.57%
0.22+18.69%
0.19-59.10%
0.46+246.59%
0.13-83.11%
0.79-64.03%
2.20-57.80%
5.22—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomic Vision Stock analysis

What does Genomic Vision do? Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomic Vision stock

Net Debt to Free Cash Flow Ratio of Genomic Vision is -0.37 in 2022.

Net Debt to Free Cash Flow Ratio of Genomic Vision changed from 0.28 to -0.37, representing a -232.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Genomic Vision since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Genomic Vision with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Genomic Vision

All Key Metrics — Genomic Vision